{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:09:38Z","timestamp":1747159778843,"version":"3.40.5"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Leiden University Medical Center, The Netherlands"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejps.2017.11.025","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T04:01:42Z","timestamp":1511841702000},"page":"24-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome"],"prefix":"10.1016","volume":"114","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2746-4537","authenticated-orcid":false,"given":"Sofieke","family":"de Wilde","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-1677","authenticated-orcid":false,"given":"Maria G.H.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander F.","family":"Lipka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten J.M.","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2011","series-title":"Letter: Subject: CHF-Rapport 11\/37: Amifampridine (Firdapse)","author":"Boer","key":"10.1016\/j.ejps.2017.11.025_bb0005"},{"key":"10.1016\/j.ejps.2017.11.025_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/COC.0000000000000251","article-title":"The orphan drug act: restoring the mission to rare diseases","volume":"39","author":"Daniel","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2017.11.025_bb0015","article-title":"Unlicensed pharmaceutical preparations for clinical patient care: Ensuring safety","author":"de Wilde","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.ejps.2017.11.025_bb0020","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.drudis.2016.04.016","article-title":"Development of cell therapy medicinal products by academic institutes","volume":"21","author":"de Wilde","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2017.11.025_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jcpt.12006","article-title":"Do we need authorized orphan drugs when compounded medications are available?","volume":"38","author":"Dooms","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"year":"2010","series-title":"Stop Exploiting Orphan Drugs. BMJ, Editor's Choice c:6587","author":"Editorial","key":"10.1016\/j.ejps.2017.11.025_bb0030"},{"key":"10.1016\/j.ejps.2017.11.025_bb0035","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(15)60420-2","article-title":"Reducing the cost of rare disease drugs","volume":"385","author":"Editorial","year":"2015","journal-title":"Lancet"},{"year":"2009","series-title":"Assessment Report for Zenas","author":"European Medicines Agency","key":"10.1016\/j.ejps.2017.11.025_bb0040"},{"year":"2014","series-title":"Guideline on the Pharmacokinetic and Clinical Evaluation 4 of Modified Release Dosage Forms 5 (EMA\/CPMP\/EWP\/280\/96 Corr1) - WC500177884.pdf","author":"European Medicines Agency","key":"10.1016\/j.ejps.2017.11.025_bb0045"},{"year":"2016","series-title":"D80 Assessment Report - Quality Guidance rev 10.16 - WC500004808.pdf","author":"European Medicines Agency","key":"10.1016\/j.ejps.2017.11.025_bb0050"},{"year":"2016","series-title":"D80 Assessment Report - Non Clinical Guidance Rev 10.16 - WC500206988.pdf","author":"European Medicines Agency","key":"10.1016\/j.ejps.2017.11.025_bb0055"},{"year":"2016","series-title":"D80 Assessment Report - Clinical Guidance Rev 10.16 - WC500206987.pdf","author":"European Medicines Agency","key":"10.1016\/j.ejps.2017.11.025_bb0060"},{"key":"10.1016\/j.ejps.2017.11.025_bb0065","article-title":"Lambert-eaton myasthenic syndrome; pathogenesis, diagnosis, and therapy","volume":"2011","author":"Gilhus","year":"2011","journal-title":"Autoimmune Dis."},{"year":"2010","series-title":"Drug Firms Accused of Exploiting Loophole for Profit","author":"Goldberg","key":"10.1016\/j.ejps.2017.11.025_bb0070"},{"key":"10.1016\/j.ejps.2017.11.025_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.99","article-title":"Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate","volume":"3","author":"Haroldsen","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejps.2017.11.025_bb0080","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.clinthera.2015.05.498","article-title":"Effects of food intake on the relative bioavailability of amifampridine phosphate salt in healthy adults","volume":"37","author":"Haroldsen","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2017.11.025_bb0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0014-2999(77)90303-X","article-title":"The actions of three diaminopyridines on the chick biventer cervicis muscle","volume":"44","author":"Harvey","year":"1977","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejps.2017.11.025_bb0090","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.clinph.2014.06.031","article-title":"Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy","volume":"125","author":"H\u00fclsbrink","year":"2014","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.ejps.2017.11.025_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0306-x","article-title":"Compassionate use of orphan drugs","volume":"10","author":"Hyry","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejps.2017.11.025_bb0100","first-page":"341","article-title":"Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine","volume":"7","author":"Lindquist","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.ejps.2017.11.025_bb0105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp.46.7.684","article-title":"Novel drug of choice in Eaton-Lambert syndrome","volume":"46","author":"Lundh","year":"1983","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejps.2017.11.025_bb0110","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40120-015-0034-0","article-title":"The European LEMS registry: baseline demographics and treatment approaches","volume":"4","author":"Mantegazza","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.ejps.2017.11.025_bb0115","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.healthpol.2014.07.010","article-title":"Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe","volume":"117","author":"Minghetti","year":"2014","journal-title":"Health Policy"},{"key":"10.1016\/j.ejps.2017.11.025_bb0120","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.drudis.2016.06.014","article-title":"Research and drug development activities in rare diseases: differences between Japan and Europe regarding influence of prevalence","volume":"21","author":"Mizoguchi","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2017.11.025_bb0125","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2012.02.010","article-title":"3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis","volume":"245","author":"Mori","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejps.2017.11.025_bb0130","doi-asserted-by":"crossref","first-page":"c6466","DOI":"10.1136\/bmj.c6466","article-title":"Open letter to prime minister David Cameron and health secretary Andrew Lansley","volume":"341","author":"Nicholl","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ejps.2017.11.025_bb0135","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mus.25070","article-title":"Amifampridine phosphate (Firdapse(\u00ae)) is effective and safe in a phase 3 clinical trial in LEMS","volume":"53","author":"Oh","year":"2016","journal-title":"Muscle Nerve"},{"author":"Orphanet","key":"10.1016\/j.ejps.2017.11.025_bb0140"},{"key":"10.1016\/j.ejps.2017.11.025_bb0145","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1185\/03007991003745209","article-title":"Current therapy for Lambert\u2013Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment","volume":"26","author":"Quartel","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejps.2017.11.025_bb0150","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/j.1749-6632.1998.tb11022.x","article-title":"3,4-Diaminopyridine (DAP) in the treatment of Lambert-Eaton myasthenic syndrome (LEMS)","volume":"841","author":"Sanders","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejps.2017.11.025_bb0155","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF01059413","article-title":"The acute oral toxicity, repellency, and hazard potential of 998 chemicals to one or more species of wild and domestic birds","volume":"12","author":"Schafer","year":"1983","journal-title":"Arch. Environ. Contam. Toxicol."},{"key":"10.1016\/j.ejps.2017.11.025_bb0160","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-015-0305-y","article-title":"The quality of economic evaluations of ultra-orphan drugs in Europe \u2013 a systematic review","volume":"10","author":"Schuller","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejps.2017.11.025_bb0165","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1007\/s12035-014-8887-2","article-title":"Synaptic pathophysiology and treatment of Lambert-Eaton myasthenic syndrome","volume":"52","author":"Tarr","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2017.11.025_bb0170","volume":"2","author":"The Rising Cost of Orphan Drugs","year":"2015","journal-title":"Lancet Haematol."},{"year":"2017","series-title":"WHO | HTA Activities at WHO [WWW Document]","author":"World Health Organization","key":"10.1016\/j.ejps.2017.11.025_bb0175"},{"author":"Zorginstituut Nederland","key":"10.1016\/j.ejps.2017.11.025_bb0180"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717306541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717306541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T14:52:14Z","timestamp":1536763934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717306541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":36,"alternative-id":["S0928098717306541"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.11.025","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The possibility of obtaining marketing authorization of orphan pharmaceutical compounding preparations: 3,4-DAP for Lambert-Eaton Myasthenic Syndrome","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.11.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}